Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China

Table 4 Early stage major complications after operation between hepatitis B virus core antibody positive liver graft recipients and hepatitis B virus core antibody negative liver graft recipients (within 30 d post liver transplantation) %

Major complication	Before propensity matching			After propensity matching
	Anti-HBc+ (n = 230)	Anti-HBc- (n = 841)	P value	Anti-HBc+ (n = 210)	Anti-HBc- (n = 210)	P value
Primary non-function	0.43 (1/230)	0.24 (2/841)	0.52	0	0	1.00
Biliary complications	0.87 (2/230)	1.30 (11/841)	0.75	0.47 (1/210)	0.47 (1/210)	1.00
Hepatic artery stenosis/embolism	2.61 (6/230)	1.54 (13/841)	0.26	2.38 (5/210)	1.43 (3/210)	0.72
Portal vein stenosis/embolism	3.91 (9/230)	2.49 (21/841)	0.25	3.33 (7/210)	0.95 (2/210)	0.17
Outflow tract stenosis/embolism	0.87 (2/230)	0.36 (3/841)	0.29	0.47 (1/210)	0.47 (1/210)	1.00
Bacterial infection	21.30 (49/230)	20.33 (171/841)	0.75	8.10 (17/210)	7.62 (16/210)	0.85
Intra-abdominal hemorrhage	7.39 (17/230)	5.35 (45/841)	0.24	5.24 (11/210)	2.38 (5/210)	0.20
Pleural effusion	10.86 (25/230)	15.21 (128/841)	0.09	5.71 (12/210)	3.33 (7/210)	0.24
Celiac effusion	11.74 (27/230)	14.86 (125/841)	0.23	7.62 (16/210)	8.10 (17/210)	0.85
Pneumonedema	0.43 (1/230)	0.36 (3/841)	> 0.9	0.47 (1/210)	0.47 (1/210)	1.00

Differences between rates were tested by Chi-square test or Fisher exact test, if appropriate.